TriangleAmivantamab (NCT05498428)
Amivantamab trial for Carcinoma, Non-small-Cell Lung (NCT05498428). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with incurable advanced non-small-cell lung cancer. Most require EGFR exon-19 deletion, L858R or exon-20 insertion; another switches intravenous amivantamab to injections.
The idea: test amivantamab under the skin with hyaluronidase. Amivantamab targets EGFR and MET growth signals. Depending on mutation and earlier treatment, partners are lazertinib, carboplatin plus pemetrexed, or both. One group also requires preventive blood thinners. Schedules differ by group. Researchers assess response and safety; the switch group focuses on safety.
This phase 2 study plans 520 patients. Janssen sponsors fourteen recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.